2 completed, 2 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Miransertib: new trials by email Literature Review of Miransertib trials Research Report on Miransertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) Miransertib - PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | Phase 1 / Phase 2 | Terminated | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 50 | 2017-05-16 | 2023-04-13 |
| Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome MK-7075 (miransertib) - Proteus Syndrome | Phase 1 | Completed | National Human Genome Research Institute (NHGRI) | 6 | 2015-11-16 | 2022-06-30 |
| Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole - Solid Tumors, Ovarian Cancer | Phase 1 | Terminated | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 41 | 2015-06-09 | 2020-09-30 |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma ARQ 092 - Solid Tumor, Malignant Lymphoma | Phase 1 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 120 | 2011-11-01 | 2017-10-23 |
Endometrial Neoplasms (2) · Neoplasms (2) · Congenital Abnormalities (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lymphoma (1) · Ovarian Neoplasms (1) · Proteus Syndrome (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (3) · National Human Genome Research Institute (NHGRI) (1)
United States (4) · Australia (1) · Italy (1) · Spain (1)
PMID 30803705, PMID 33639990, PMID 34649967, PMID 40713644
2016 (1)